Cumberland Pharmaceuticals Inc. (CPIX)
NASDAQ: CPIXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CPIX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $87.57M
- Forward P/E
- 41.71
- EPS (TTM)
- -$0.57
- Dividend yield
- None
- Ex-dividend date
- Aug 3, 2026
- 52-week range
- 2.00 – 9.28
- Day range
- 5.74 – 6.44
- Volume / Avg
- 118.08K / 114.52K
- Beta
- —
- Shares outstanding
- 15.00M
52-week range
CPIX stock today
On Nov 20, CPIX ended the session at $5.84, shedding $0.46 (7.30%), versus the S&P 500's 3.70% decline. At this level, CPIX sits in the middle of its 52-week range of $2.00 to $9.28: 37.1% below the high, set on Aug 26, 2026 and 192.0% above the low. CPIX is up 46.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 193.5%.
Cumberland Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$0.57), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Cumberland Pharmaceuticals
Company profileCumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. A. J. Kazimi MBA
- Headquarters
- Nashville, TN
- Employees
- 88
- IPO year
- 2009
- Website
- cumberlandpharma.com
Financial highlights
Full financialsIn fiscal 2025, Cumberland Pharmaceuticals generated $44.5 million in revenue, up 17.6% from fiscal 2024. Cumberland Pharmaceuticals reported a net loss of $2.8 million, compared with a loss of $6.5 million a year earlier. Gross margin was 85.0% (up from 82.6%) and operating margin -6.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $44.52M | $37.87M | $39.55M | $42.01M | $35.99M |
| Growth | +17.57% | -4.26% | -5.85% | +16.75% | -3.89% |
| Net income | $-2.84M | $-6.48M | $-6.28M | $-5.57M | $-3.51M |
| EPS (diluted) | $-0.19 | $-0.46 | $-0.44 | $-0.38 | $-0.24 |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.06 vs —
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $1.50
- Ex-dividend date
- Aug 3, 2026
CPIX news
All CPIX news- Cumberland Pharmaceuticals Inc. Announces Phase 2a ASSIST-SSc Trial Top-Line ResultsNasdaq
- Cumberland Pharmaceuticals Inc. Announces Plans to File New Drug Application for Ifetroban DMD ProgramNasdaqCPIX, HEI.A
- CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATEPR Newswire
- CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q3 2026 FINANCIAL RESULTSPR Newswire
- CUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAMPR Newswire
- Cumberland Pharma Reports Phase 2a Safety Data For Ifetroban In Systemic Sclerosis; Shares SlideNasdaqCPIX, HEI.A
- Cumberland Pharmaceuticals Inc. Announces Top-Line Results from Phase 2a ASSIST-SSc TrialNasdaq
- Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line ResultsPR Newswire
Cumberland Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RTSNRetension Pharmaceuticals Inc. | 10.51 | -19.22% | $87.57M | vs CPIX |
| EQEquillium Inc. | 1.06 | -5.36% | $87.26M | vs CPIX |
| UPBUpstream Bio Inc. | 1.59 | -20.50% | $87.15M | vs CPIX |
| ANIXAnixa Biosciences Inc. | 2.44 | -6.15% | $84.82M | vs CPIX |
| NTHINeOnc Technologies Holdings Inc. | 3.15 | -9.48% | $90.88M | vs CPIX |
| CATXPerspective Therapeutics Inc. | 0.7538 | -3.85% | $91.03M | vs CPIX |
| CLLSCellectis S.A. ADR | 0.9209 | -7.89% | $92.76M | vs CPIX |
| OGIOrganigram Global Inc. | 0.583 | -7.40% | $82.27M | vs CPIX |
Indexes, lists and sector
Cumberland Pharmaceuticals stock FAQ
What is Cumberland Pharmaceuticals's stock price today?
CPIX last traded at $5.84 as of Nov 20, 4:00 PM EST, down 7.30% on the day. Prices are delayed at least 15 minutes.
Does Cumberland Pharmaceuticals pay a dividend?
Yes. Cumberland Pharmaceuticals pays $0.00 per share annually. The most recent dividend of $1.50 had an ex-dividend date of Aug 3, 2026.
Who is Cumberland Pharmaceuticals's CEO?
Mr. A. J. Kazimi MBA is the chief executive officer of Cumberland Pharmaceuticals Inc., which has about 88 employees.
What is the CPIX 52-week high?
The 52-week high for CPIX is $9.28 and the 52-week low is $2.00. The stock is currently 37.1% below its high.